A Synthetic Steroid 5Α-Androst-3β, 5, 6Β-Triol Alleviates Radiation-Induced Brain Injury in Mice Via Inhibiting GBP5/NF-κB/NLRP3 Signal Axis.
Ke Zhong,Kejia Liu,Yu Song,Sitai Chen,Xia Hu,Ruiqi Xue,Xueying Ma,Shaojian Li,Jingwen Yang,Zhenhong Deng,Xiaoqiu Zhu,Mingjun Yuan,Yijun Huang,Wei Yin,Yupin Chen,Yamei Tang,Zhongshan Shi
DOI: https://doi.org/10.1007/s12035-023-03831-9
IF: 5.682
2023-01-01
Molecular Neurobiology
Abstract:Radiotherapy for head and neck tumors can lead to a severe complication known as radiation-induced brain injury (RIBI). However, the underlying mechanism of RIBI development remains unclear, and limited prevention and treatment options are available. Neuroactive steroids have shown potential in treating neurological disorders. 5 alpha-Androst-3 beta, 5, 6 beta-triol (TRIOL), a synthetic neuroprotective steroid, holds promise as a treatment candidate for RIBI patients. However, the neuroprotective effects and underlying mechanism of TRIOL on RIBI treatment are yet to be elucidated. In the present study, our findings demonstrate TRIOL's potential as a neuroprotective agent against RIBI. In gamma knife irradiation mouse model, TRIOL treatment significantly reduced brain necrosis volume, microglial activation, and neuronal loss. RNA-sequencing, immunofluorescence, real-time quantitative polymerase chain reaction, siRNA transfection, and western blotting techniques revealed that TRIOL effectively decreased microglial activation, proinflammatory cytokine release, neuron loss, and guanylate-binding protein 5 (GBP5) expression, along with its downstream signaling pathways NF-kappa B and NLRP3 activation in vitro. In summary, TRIOL effectively alleviate RIBI by inhibiting the GBP5/NF-kappa B/NLRP3 signal axis, reducing microglia activation and pro-inflammation cytokines release, rescuing neuron loss. This study highlights the potential of TRIOL as a novel and promising therapy drug for RIBI treatment.